Germany Legalizes Cannabis, Sparking EU-Wide Debate
Germany becomes the third EU country to legalize cannabis, aiming to curb the illegal market but raising concerns about youth consumption; the move also boosts the medical cannabis market, yet faces potential repeal by conservative parties.
Germany Legalizes Cannabis, Sparking EU-Wide Debate
Germany becomes the third EU country to legalize cannabis, aiming to curb the illegal market but raising concerns about youth consumption; the move also boosts the medical cannabis market, yet faces potential repeal by conservative parties.
Progress
32% Bias Score
Full-Spectrum Cannabis Drug Shows Promise in Autism Treatment
Ajna BioSciences, in collaboration with Charlotte's Web and British American Tobacco, is developing AJA001, a full-spectrum hemp-derived cannabinoid drug for autism spectrum disorder (ASD), which successfully completed Phase 1 trials demonstrating safety and efficacy, and plans to launch Phase 2 tri...
Full-Spectrum Cannabis Drug Shows Promise in Autism Treatment
Ajna BioSciences, in collaboration with Charlotte's Web and British American Tobacco, is developing AJA001, a full-spectrum hemp-derived cannabinoid drug for autism spectrum disorder (ASD), which successfully completed Phase 1 trials demonstrating safety and efficacy, and plans to launch Phase 2 tri...
Progress
44% Bias Score
Kentucky Launches Medical Cannabis Directory
Kentucky is launching an online directory to connect patients with medical cannabis providers as its medical cannabis program begins in 2025.
Kentucky Launches Medical Cannabis Directory
Kentucky is launching an online directory to connect patients with medical cannabis providers as its medical cannabis program begins in 2025.
Progress
36% Bias Score
France's Medical Cannabis Crossroads: Balancing Caution and Patient Needs
In France, medical cannabis remains largely prohibited despite a small trial program and growing patient advocacy; the high cost of GMP-compliant production, stringent regulatory requirements, and the socialized healthcare system create obstacles to broader access, highlighting a conflict between ca...
France's Medical Cannabis Crossroads: Balancing Caution and Patient Needs
In France, medical cannabis remains largely prohibited despite a small trial program and growing patient advocacy; the high cost of GMP-compliant production, stringent regulatory requirements, and the socialized healthcare system create obstacles to broader access, highlighting a conflict between ca...
Progress
64% Bias Score
France's Medical Cannabis Trial Ends: Uncertainty Remains
France's medical cannabis trial, launched in March 2021, will end December 31, 2024, affecting 1,800 patients; a six-month transition period will help them switch to other treatments, while the future of medical cannabis in France remains uncertain due to political factors and lack of transparency.
France's Medical Cannabis Trial Ends: Uncertainty Remains
France's medical cannabis trial, launched in March 2021, will end December 31, 2024, affecting 1,800 patients; a six-month transition period will help them switch to other treatments, while the future of medical cannabis in France remains uncertain due to political factors and lack of transparency.
Progress
36% Bias Score